INX-315
CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer; CCNE1-Amplified Solid Tumors
Phase 1/2Active
Key Facts
Indication
CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer; CCNE1-Amplified Solid Tumors
Phase
Phase 1/2
Status
Active
Company
About Incyclix Bio
Incyclix Bio is a private, clinical-stage biotechnology company developing selective CDK inhibitors for cancer, with a lead asset, INX-315, in Phase 1/2 trials for CDK4/6i-resistant breast cancer and CCNE1-amplified solid tumors. The company leverages deep, foundational expertise from the team that previously built G1 Therapeutics and advanced trilaciclib to market. Backed by a recent $11.25 million Series B extension and recognized as a 'Fierce 15' company, Incyclix aims to address a significant unmet need in overcoming resistance to first-generation CDK4/6 inhibitors.
View full company profile